Cyprotex forges first US partnership
Cyprotex, the drug discovery technology and information company, has entered into a long-term agreement with US-based Sepracor concerning its integrated Cloe offering. The 'seven figure deal' involves rolling 12-month contracts, and will install Sepracor as Cyprotex's primary client, 'providing 14-15% of annual turnover'.
Cyprotex, the drug discovery technology and information company, has entered into a long-term agreement with US-based Sepracor concerning its integrated Cloe offering. The 'seven figure deal' involves rolling 12-month contracts, and will install Sepracor as Cyprotex's primary client, 'providing 14-15% of annual turnover'.
Commenting on the agreement, Robert Morrisson Atwater, ceo of Cyprotex, said: 'this, as the company's first major US partnership, shows that its technologies, expertise and general approach are attracting a wider audience'.
The Cloe Screen suite of assays is able to generate detailed profiles of a customer's compounds to include their absorption, distribution, metabolism, excretion and toxicity (ADME) properties. A partnership is structured with customers to provide early evaluation of compounds to support decision-making on the selection of lead series to take forward, in addition to providing follow-up experimental support for further investigation of potential liabilities on smaller groups of compounds. This also provides a steady supply of critical information for guiding a customer's lead opti-misation and compound selection for clinical trials.